FDA-approved PSMA PET agents, such as [68Ga]-PSMA-11 and [18F]-DCFPyL, provide high diagnostic accuracy and are indispensable for the management of prostate cancer. This evidence concerns the gene FOLH1 and prostate carcinoma.